2024 / 25 has continued our evolution from the generation of value from the historical product set of core antibodies into a business with increasing expertise and reach in the creation of antibodies for application in the diagnosis of a range of neurological conditions and diseases.
A snapshot of some key figures from the year ending June 2025.
£13.1M
Turnover
£605k
Total Tau/neuro SMA sales during the year increased fourfold from £155k in 2023/24 to £605k.
12
FTEs
3
Tau antibodies being made at scale with 3 more moving into production
£6.6M
Sales of vitD3.5H10 increased by 12%.
Financial year 2024/25
Over the course of the financial year 2024/25 our activities in the increasingly important field of neurology diagnostics have advanced, not only in our work with academic partners on the underlying science, but also on the development of key products and commercial relationships with our IVD customers. We now have three Tau antibodies being made at scale in our manufacturing facility. In addition to this, three newer antibodies are currently moving into large scale production. We have been delighted with the response to evaluation samples of antibodies supplied to our customers and our SMAs now feature in several Research use Only (“RuO”) assays. These RuO assays are being commercialised by specialist high sensitivity platform companies, such as Quanterix and Alamar, as well as being provided by IVD companies for evaluation on a global scale.
2024/25 has been part of an evolution from the generation of value from the historical product set of core antibodies into a business with increasing expertise and reach in the creation of antibodies for application in the diagnosis of a range of conditions and diseases.
This antibody is used by a significant number of diagnostic companies around the world for use in vitamin D deficiency testing.
Peripheral neuropathy and cerebral amyloid angiopathy are two research activities being undertaken.
Continued collaboration with world-leading research facility; University of Gothenburg.
We now have sensitive lab-based ELISA assays that can detect levels of drugs equating to 0.1-1.0% of raw sewage contamination in “fresh” waters.
We have now completed a second manufacturing batch of our pyrene lateral flow system for industrial pollution biomonitoring.
Tau sales during the year increased from £155k in 2023/24 to £605k.
This antibody is used by a significant number of diagnostic companies around the world for use in vitamin D deficiency testing.
Peripheral neuropathy and cerebral amyloid angiopathy are two research activities being undertaken.
Continued collaboration with world-leading research facility; University of Gothenburg.
We now have sensitive lab-based ELISA assays that can detect levels of drugs equating to 0.1-1.0% of raw sewage contamination in “fresh” waters.
We have now completed a second manufacturing batch of our pyrene lateral flow system for industrial pollution biomonitoring.
Tau sales during the year increased from £155k in 2023/24 to £605k.
Looking Ahead
“This year has been particularly noteworthy as our historic core business has faced some challenges in downstream markets, particularly in China. Meanwhile, our research and commercialisation of antibodies in the field of neurology has experienced significant progress. The vision of our customers for growth in this exciting field together with the performance of our antibodies at many of our customers points to future success in this area.”
— Ian Nicholson & Peter Harrison